Skip to main content
Top
Published in: World Journal of Urology 2/2014

01-04-2014 | Topic Paper

The use of immediate postoperative instillations of intravesical chemotherapy after TURBT of NMIBC among European countries

Authors: Juan Palou-Redorta, Morgan Rouprêt, Jack R. Gallagher, Kylee Heap, Catherine Corbell, Brent Schwartz

Published in: World Journal of Urology | Issue 2/2014

Login to get access

Abstract

Purpose

The aim of this study was to assess the use of immediate postoperative instillation of intravesical chemotherapy (IPOIC) after transurethral resection of bladder tumour (TURBT) of nonmuscle invasive bladder cancer (NMIBC) in Europe.

Methods

Urologists based in five European Union nations were asked to extract information from the records of patients with NMIBC–urothelial carcinoma who received at least one TURBT. Multivariate logistic regression models were developed to determine the significant predictors of IPOIC usage. Data were weighted to control for country-to-country and other differences.

Results

Overall, 324 urologists (58 France, 72 Germany, 62 Italy, 65 Spain, 67 United Kingdom) were involved; the participation rate was 55 %. Overall, 771 patients received 954 TURBTs (mean—1.2/patient), of which 413 of the TURBTs (43.3 %) were administered IPOIC . Sixty-six of the 413 IPOICs (16.0 %) were for a recurrent tumour. Five of the tested variables were significantly associated with a patient’s likelihood of receiving IPOIC after TURBT. Variables in the order of significance are as follows: (1) country (United Kingdom, patients most likely to receive IPOIC; France, least likely); (2) progression risk (physician assessed) [lower-risk conditions (no CIS, tumour < 3 cm) or intermediate risk—more likely]; (3) whether urologist completed a uro-oncology fellowship (completed—more likely); (4) recurrence risk (physician assessed) [higher-risk conditions (≥T2, ≥3 cm, CIS)—more likely]; and (5) physician’s NMIBC patients volume (higher volume—more likely).

Conclusions

This study revealed wide practice variation and substantial noncompliance with European Association of Urology Guidelines on the use of IPOIC after TURBT for NMIBC.
Literature
1.
go back to reference Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J (2008) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 54:303–314PubMedCrossRef Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J (2008) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 54:303–314PubMedCrossRef
2.
go back to reference van Rhijn BW, van der Kwast TH, Alkhateeb SS, Fleshner NE, van Leenders GJ, Bostrom PJ et al (2012) A new and highly prognostic system to discern T1 bladder cancer substage. Eur Urol 61:378–384PubMedCrossRef van Rhijn BW, van der Kwast TH, Alkhateeb SS, Fleshner NE, van Leenders GJ, Bostrom PJ et al (2012) A new and highly prognostic system to discern T1 bladder cancer substage. Eur Urol 61:378–384PubMedCrossRef
3.
4.
go back to reference Lim D, Izawa JI, Middlebrook P, Chin JL (2010) Bladder perforation after immediate postoperative intravesical instillation of mitomycin C. Can Urol Assoc J 4(1):E1–E3 Lim D, Izawa JI, Middlebrook P, Chin JL (2010) Bladder perforation after immediate postoperative intravesical instillation of mitomycin C. Can Urol Assoc J 4(1):E1–E3
5.
go back to reference Oosterlinck W, Sylvester R, Babjuk M, Kaasinen E, Bohle A, Palou-Redorta J et al (2011) Should all patients receive an immediate chemotherapeutic drug instillation after resection of papillary bladder tumors? Eur Urol 59:374–376PubMedCrossRef Oosterlinck W, Sylvester R, Babjuk M, Kaasinen E, Bohle A, Palou-Redorta J et al (2011) Should all patients receive an immediate chemotherapeutic drug instillation after resection of papillary bladder tumors? Eur Urol 59:374–376PubMedCrossRef
6.
go back to reference Sylvester RJ, Oosterlinck W, van der Meijden AP (2004) A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 171:2186–2190 quiz 2435PubMedCrossRef Sylvester RJ, Oosterlinck W, van der Meijden AP (2004) A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 171:2186–2190 quiz 2435PubMedCrossRef
7.
go back to reference Dobruch J, Herr H (2009) Should all patients receive single chemotherapeutic agent instillation after bladder tumour resection? BJU Int 104:170–174PubMedCrossRef Dobruch J, Herr H (2009) Should all patients receive single chemotherapeutic agent instillation after bladder tumour resection? BJU Int 104:170–174PubMedCrossRef
8.
go back to reference Cookson MS, Chang SS, Oefelein MG, Gallagher JR, Schwartz B, Heap K (2012) National practice patterns for immediate postoperative instillation of chemotherapy in nonmuscle invasive bladder cancer. J Urol 187:1571–1576PubMedCrossRef Cookson MS, Chang SS, Oefelein MG, Gallagher JR, Schwartz B, Heap K (2012) National practice patterns for immediate postoperative instillation of chemotherapy in nonmuscle invasive bladder cancer. J Urol 187:1571–1576PubMedCrossRef
9.
go back to reference European Pharmaceutical Marketing Research Association (EphMRA) (2008) Foundation Committee Report. Doctor Statistics in Canada, France, Germany, Italy, Japan, Spain, UK, USA European Pharmaceutical Marketing Research Association (EphMRA) (2008) Foundation Committee Report. Doctor Statistics in Canada, France, Germany, Italy, Japan, Spain, UK, USA
10.
go back to reference Brausi M, Witjes JA, Lamm D, Persad R, Palou J, Colombel M et al (2011) A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol 186:2158–2167PubMedCrossRef Brausi M, Witjes JA, Lamm D, Persad R, Palou J, Colombel M et al (2011) A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol 186:2158–2167PubMedCrossRef
11.
go back to reference Colonna M, Bossard N, Guizard AV, Remontet L, Grosclaude P (2010) Descriptive epidemiology of thyroid cancer in France: incidence, mortality and survival. Ann Endocrinol (Paris) 71:95–101CrossRef Colonna M, Bossard N, Guizard AV, Remontet L, Grosclaude P (2010) Descriptive epidemiology of thyroid cancer in France: incidence, mortality and survival. Ann Endocrinol (Paris) 71:95–101CrossRef
12.
go back to reference Chamie K, Saigal CS, Lai J, Hanley JM, Setodji CM, Konety BR et al (2011) Compliance with guidelines for patients with bladder cancer: variation in the delivery of care. Cancer 117:5392–5401PubMedCentralPubMedCrossRef Chamie K, Saigal CS, Lai J, Hanley JM, Setodji CM, Konety BR et al (2011) Compliance with guidelines for patients with bladder cancer: variation in the delivery of care. Cancer 117:5392–5401PubMedCentralPubMedCrossRef
13.
go back to reference Mariappan P, Zachou A, Grigor KM (2010) Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. Eur Urol 57:843–849PubMedCrossRef Mariappan P, Zachou A, Grigor KM (2010) Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. Eur Urol 57:843–849PubMedCrossRef
14.
go back to reference Berrum-Svennung I, Granfors T, Jahnson S, Boman H, Holmang S (2008) A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences. J Urol 179:101–105 Discussion 105–106PubMedCrossRef Berrum-Svennung I, Granfors T, Jahnson S, Boman H, Holmang S (2008) A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences. J Urol 179:101–105 Discussion 105–106PubMedCrossRef
15.
go back to reference Gudjonsson S, Adell L, Merdasa F, Olsson R, Larsson B, Davidsson T et al (2009) Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur Urol 55:773–780PubMedCrossRef Gudjonsson S, Adell L, Merdasa F, Olsson R, Larsson B, Davidsson T et al (2009) Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur Urol 55:773–780PubMedCrossRef
16.
go back to reference Di Stasi SM, Valenti M, Verri C, Liberati E, Giurioli A, Leprini G et al (2011) Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. Lancet Oncol 12:871–879PubMedCrossRef Di Stasi SM, Valenti M, Verri C, Liberati E, Giurioli A, Leprini G et al (2011) Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. Lancet Oncol 12:871–879PubMedCrossRef
Metadata
Title
The use of immediate postoperative instillations of intravesical chemotherapy after TURBT of NMIBC among European countries
Authors
Juan Palou-Redorta
Morgan Rouprêt
Jack R. Gallagher
Kylee Heap
Catherine Corbell
Brent Schwartz
Publication date
01-04-2014
Publisher
Springer Berlin Heidelberg
Published in
World Journal of Urology / Issue 2/2014
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-013-1142-z

Other articles of this Issue 2/2014

World Journal of Urology 2/2014 Go to the issue